<DOC>
	<DOCNO>NCT00010335</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine safety long term complication total body irradiation combination cyclophosphamide , anti-thymocyte globulin , autologous CD34-selected peripheral blood stem cell ( PBSC ) transplantation child refractory autoimmune disorder . II . Determine efficacy treatment regimen patient . III . Determine reconstitution immunity autologous CD34-selected PBSC transplantation patient . IV . Determine engraftment autologous CD34-selected PBSC patient .</brief_summary>
	<brief_title>Pilot Study Total Body Irradiation Combination With Cyclophosphamide , Anti-thymocyte Globulin , Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation Children With Refractory Autoimmune Disorders</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This multicenter study . Patients receive filgrastim ( G-CSF ) subcutaneously daily peripheral blood stem cell ( PBSC ) collection complete . CD34+ cell separate rest PBSCs . Patients undergo total body irradiation twice daily day -5 -4 . Patients receive anti-thymocyte globulin IV day -5 , -3 , -1 , 1 , 3 , 5 cyclophosphamide IV day -3 -2 . CD34-selected PBSCs reinfused day 0 . Patients receive G-CSF IV daily begin day 0 continue blood count recover . Patients follow annually 5 year every 5 year thereafter .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Dermatomyositis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis 1 follow base American College Rheumatology ( ACR ) Criteria : Severe juvenile rheumatoid arthritis ( systemic onset polyarticular course ) Juvenile systemic lupus erythematosus Systemic sclerosis Dermatomyositis Refractory standard aggressive therapy OR unacceptable toxicity standard therapy Reasonable expectation possible improvement evidence good potential rehabilitation therapy adequate social factor No serious CNS damage would preclude significant functional recovery Prior/Concurrent Therapy Chemotherapy : At least 4 week since prior methotrexate cyclophosphamide Endocrine therapy : At least 4 week since prior intraarterial steroid Juvenile rheumatoid arthritis patient continue steroid without taper throughout mobilization harvest stem cell If receiving corticosteroid , must continue without taper Other : At least 4 week since prior antiinflammatory agent nonsteroidal antiinflammatory drug ( NSAIDs ) sulfasalazine At least 4 week since prior cyclosporine , tacrolimus , mycophenolate mofetil , azathioprine , penicillamine , etanercept Patient Characteristics Life expectancy : At least 30 day Hematopoietic : Absolute neutrophil count least 1,000/mm3 OR Platelet count least 100,000/mm3 No bone marrow aspirate biopsy consistent production defect ( depletion neutrophil precursor megakaryocyte ) No myelodysplasia Hepatic : Bilirubin great 2.5 mg/dL AST great 300 U/L two sequential test No severe liver dysfunction within past month No active hepatitis A , B , C Renal : No endstage glomerulonephritis renal disease Creatinine clearance least 40 mL/min Cardiovascular : No uncontrolled malignant arrhythmia No New York Heart Association class III IV congestive heart failure Ejection fraction least 50 % Pulmonary : DLCO least 45 % ( DLCO least 70 % patient pulmonary disease cause documented process primary autoimmune disorder , infectious pneumonia aspiration pneumonia ) No severe pulmonary hypertension ( PAP great 50 ) without potential significant improvement Other : No medical psychosocial reason would make hematopoietic stem cell collection intolerable No increase anesthetic risk No fever high 39 degree C No positive serology toxoplasmosis No active life threaten infection responsive therapy No disease organ dysfunction would limit survival No known hypersensitivity murine equine proteins No known primary immunodeficiency disease HIV negative</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>arthritis &amp; connective tissue disease</keyword>
	<keyword>dermatomyositis</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>juvenile rheumatoid arthritis</keyword>
	<keyword>rare disease</keyword>
	<keyword>systemic lupus erythematosus</keyword>
	<keyword>systemic sclerosis</keyword>
</DOC>